HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Kidney transplant failure and rejection — Clinical Guidelines

Overview

Kidney transplant failure encompasses both graft rejection and non-rejection-related complications leading to loss of allograft function. Antibody-mediated rejection (AMR) and other forms of rejection significantly contribute to transplant failure, necessitating precise diagnosis and management strategies.

Diagnosis

Biopsy-proven rejection: Essential for diagnosing AMR and other forms of rejection 1 12.

Banff classification: Utilized for grading rejection severity; diagnostic misinterpretation can impact treatment 5.

eGFR monitoring: Regular assessment to identify declining graft function 1.

Immunosuppressive drug levels: Monitoring to ensure adequate immunosuppression 6.

Histopathology and immunofluorescence: Techniques to localize immunoglobulins and complement in graft tissues 15.

Management

First-line treatments:

- Immunosuppression adjustment: Increase or switch to more potent agents like calcineurin inhibitors or mTOR inhibitors 1 6. - Antibody removal: Use plasmapheresis or intravenous immunoglobulin (IVIG) for AMR 5.

Adjunctive therapies:

- Granulocyte colony-stimulating factor (G-CSF): To manage neutropenia and reduce infection risk in pediatric patients 3. - Telehealth follow-up: For routine monitoring, improving accessibility and reducing hospital burden 4.

Special Populations

Pediatrics: AMR treatment outcomes require further study; G-CSF use can manage neutropenia 1 3.

Comorbidities: Management of drug interactions is crucial in polypharmacy scenarios post-transplant 6.

Key Recommendations

Utilize Banff classification for accurate diagnosis and grading of rejection to guide therapeutic decisions (Evidence: Moderate 5).

Regular monitoring of eGFR and immunosuppressive drug levels is essential for early detection of graft dysfunction (Evidence: Moderate 1 6).

Adjust immunosuppressive therapy based on biopsy findings to prevent rejection and manage AMR effectively (Evidence: Moderate 1 5).

Consider telehealth services for routine follow-up to enhance patient convenience and reduce healthcare costs (Evidence: Weak 4).

Evaluate and manage neutropenia with G-CSF in pediatric transplant recipients to mitigate infection risks (Evidence: Moderate 3).

References

1 Ashoor IF, Engen RM, Puliyanda D, Hayde N, Peterson CG, Zahr RS et al.. Antibody-mediated rejection in pediatric kidney transplant recipients: A report from the Pediatric Nephrology Research Consortium. Pediatric transplantation 2024. link 2 Alhamad T, Murad H, Dadhania DM, Pavlakis M, Parajuli S, Concepcion BP et al.. The Perspectives of General Nephrologists Toward Transitions of Care and Management of Failing Kidney Transplants. Transplant international : official journal of the European Society for Organ Transplantation 2023. link 3 Engen RM, Weng PL, Shih W, Patel HP, Richardson K, Dowdrick SL et al.. Outcomes of granulocyte colony-stimulating factor use in pediatric kidney transplant recipients: A Pediatric Nephrology Research Consortium study. Pediatric transplantation 2022. link 4 Andrew N, Barraclough KA, Long K, Fazio TN, Holt S, Kanhutu K et al.. Telehealth model of care for routine follow up of renal transplant recipients in a tertiary centre: A case study. Journal of telemedicine and telecare 2020. link 5 Schinstock CA, Sapir-Pichhadze R, Naesens M, Batal I, Bagnasco S, Bow L et al.. Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2019. link 6 Bril F, Castro V, Centurion IG, Espinosa J, Keller GA, Gonzalez CD et al.. A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients. Current drug safety 2016. link 7 Goldade K, Sidhwani S, Patel S, Brendt L, Vigliaturo J, Kasiske B et al.. Kidney transplant patients' perceptions, beliefs, and barriers related to regular nephrology outpatient visits. American journal of kidney diseases : the official journal of the National Kidney Foundation 2011. link 8 Solez K. History of the Banff classification of allograft pathology as it approaches its 20th year. Current opinion in organ transplantation 2010. link 9 Israni AK, Snyder JJ, Skeans MA, Tuomari AV, Maclean JR, Kasiske BL. Who is caring for kidney transplant patients? Variation by region, transplant center, and patient characteristics. American journal of nephrology 2009. link 10 Land W. Innate alloimmunity: history and current knowledge. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2007. link 11 Carrafiello G, Laganà D, Mangini M, Cuffari S, Cafaro T, Recaldini C et al.. The role of interventional radiology in the management of kidney transplant complications. La Radiologia medica 2005. link 12 Dean DE, Kamath S, Peddi VR, Schroeder TJ, First MR, Cavallo T. A blinded retrospective analysis of renal allograft pathology using the Banff schema: implications for clinical management. Transplantation 1999. link 13 Cardella JF, Hunter DW, Hulbert J, Young AT, Castaneda-Zuniga W, Amplatz K. Obstructed calycocystostomy site in association with a transplanted kidney: percutaneous management. Radiology 1985. link 14 Lurie A, Pfeffermann R, Butt K, Kountz SL. Transplant nephrectomy and simultaneous second graft retransplantation. Israel journal of medical sciences 1976. link 15 Andres GA, Accinni L, Hsu KC, Penn I, Porter KA, Rendall JM et al.. Human renal transplants. 3. Immunopathologic studies. Laboratory investigation; a journal of technical methods and pathology 1970. link

Kidney transplant failure and rejection